Partners
Partners

Co-Coordinator: Universitätsklinikum Hamburg-Eppendorf


Prof. Dr. Klaus Pantel

 

Principal Investigator

 

Phone: +49 (0) 40 7410-53503

undefinedE-Mail

 

Universitätsklinikum Hamburg-Eppendorf

Department of Tumor Biology

Martinistr. 52

20246 Hamburg

Germany

undefinedWebsite

CANCER-ID Team Hamburg

 

Dr. Anna Babayan

Postdoctoral Scientist

 

phone: +49 40 7410 51914

 

undefinedE-Mail

 

Prof. Dr. Harriet Wikman

Group Leader

 

undefinedE-Mail

 

 

Claudia Hille

PhD Student

 

undefinedE-Mail

Dr. Natalie Reimers

Postdoctoral Scientist

 

phone: +49 40 7410 51975

 

undefinedE-Mail

Institute presentation

The University Medical Center Hamburg-Eppendorf (UKE) is the largest among Hamburg's hospitals with approximately 1460 hospital beds. Each year the medical center treats around 80.000 in-patients. Additionally, approximately 260 000 out-patients as well as 113 000 emergency patients are treated. All common diseases are treated. Patients with complex diseases, cancer, and other disorders requiring a comprehensive treatment benefit from the interdisciplinary cooperation within the UKE. The UKE has formed the Comprehensive Cancer Centre (UCCH), comprising both, interdisciplinary cancer patient care and interdisciplinary cancer research matching the highest standards. Based on international peer review, the UCCH was awarded by the Deutsche Krebshilfe to be 1 of 11 “Top Centres of Excellence” (“Spitzenzentren”) in cancer care and cancer research in Germany. Breast, prostate, colorectal, and lung cancer are key focus indications of cancer research at the UKE. For the proposed project, we aim to collect peripheral blood from cohorts of breast and lung cancer patients. The clinical work-up of all patients will be performed according to the international guidelines. The Institute of Tumour Biology has a strong focus on translational research on cancer metastasis (in particular circulating and disseminated cancer cells and cell-free (cf) DNA/RNA) and is part of the UCCH. All relevant methodical aspects of patient recruitment, blood sampling, and CTC/ctDNA/cfRNA detection/characterization are well established and documented in our institution due to several previous and ongoing (but nor overlapping) projects. The pioneer work of Prof. Pantel and his team in the field of cancer micrometastasis, circulating tumour cells, and ctDNA as well as cfRNA is reflected by more than 300 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, PNAS, JCO, JNCI, Cancer Res.) and has been awarded recently (AACR Outstanding Investigator Award for Breast Cancer Research 2010, German Cancer Award 2010, ERC Advanced Investigator Grant 2011). Moreover, Prof Pantel is member of the Editorial Boards of several international cancer journals (e.g., Cancer Res., Clin. Cancer Res., Breast Cancer Res.) and organizer of international symposia (ISMRC) on minimal residual cancer and circulating tumour cells. K. Pantel is experienced in the scientific management of European networks in the field of tumour cell dissemination (e.g., coordinator of the FP6 STREP “DISMAL” (Disseminated Malignancies) and FP7 ERA-NET TRANSCAN project “CTC-SCAN”), and recipient of an ERC Advanced Investigator Grant.

CANCER-ID Consortium

CANCER-ID consortium

CANCER-ID Workpackages

CANCER-ID Work Plan

EUROPA - NEWS

News from the European Comission

What's new in Health and Life Sciences? Click here for news from the European Commission.

Search
Top
Home
Menu

EU logo
imi Logo
efpia Logo

News Section

Download the latest version of the free software that has been developed by our... Read more

Social Media

LinkedIn Cancer-ID